Current Report Filing (8-k)
May 12 2022 - 06:14AM
Edgar (US Regulatory)
false 0001641489 0001641489 2022-05-12
2022-05-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of
earliest event reported): May 12, 2022
vTv Therapeutics
Inc.
(Exact name of
registrant as specified in its charter)
|
|
|
Delaware
(State or other jurisdiction
of incorporation)
|
001-37524
(Commission File No.)
|
47-3916571
(IRS Employer
Identification No.)
|
|
3980 Premier Drive, Suite 310
High Point, NC 27265
(Address of principal executive offices)
|
(336) 841-0300
(Registrant’s telephone number, including area
code)
NOT APPLICABLE
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2.
below):
☐
|
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
☐
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a‑12)
|
☐
|
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Class A common stock, par value $0.01 per share
|
VTVT
|
NASDAQ Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02 Results of Operations and Financial Condition
On May 12, 2022, vTv Therapeutics Inc. issued a press release to
announce its financial results for the fiscal period ended March
31, 2022. A copy of the press release is attached as
Exhibit 99.1 to this current report on Form 8-K and is incorporated
herein by reference.
The information in this report (including Exhibit 99.1) shall not
be deemed to be “filed” for purposes of Section 18, of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section, and shall
not be incorporated by reference into any registration statement or
other document filed under the Securities Act of 1933, as amended
or the Exchange Act, except as shall be expressly set forth by
specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, hereunto duly authorized.
VTV THERAPEUTICS INC.
|
|
By:
|
/s/ Richard S. Nelson
|
Name:
|
Richard S. Nelson
|
Title:
|
Interim Chief Executive Officer
|
Dated: May 12, 2022
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Jan 2023 to Feb 2023
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Feb 2022 to Feb 2023